Send us a text

This week, Amol and Nathan discuss breast cancer and colorectal cancer: Two randomized control trials compared the aromatase inhibitor anastrozole to tamoxifen as adjuvant hormone therapy for postmenopausal women with ductal carcinoma in situ. Both trials were double blind and multi-centred, with one trial (NSABP B-35) enrolling North American patients and the other (IBIS-II DCIS) ...

The post Together Again: Aromatase Inhibitor for DCIS and New Colorectal Cancer Screening Recommendations appeared first on Healthy Debate.